Facilitators and Barriers to Smart Insulin Pen Use: A Mixed-Method Study of Multidisciplinary Stakeholders From Diabetes Teams in the United States.
Emma OspeltNudrat NoorJanine SanchezGrace NelsonNicole RiolesFaisal S MalikMarina BasinaJustin IndykFrancesco VendrameJessica SchmittMary L ScottOsagie A EbekozienPublished in: Clinical diabetes : a publication of the American Diabetes Association (2022)
This study sought to identify barriers and facilitators to successful smart insulin pen (SIP) use and gauge prescribing practices and integration into clinical practice by assessing provider and care team perspectives at participating endocrinology clinics within the T1D Exchange Quality Improvement Collaborative. The identified provider-related, patient-related, and clinic- and operational-level barriers and facilitators varied based on clinic knowledge, capacity, and resources. High-impact barriers included insurance coverage and prescribing processes; high-impact facilitators included improved diabetes clinic visit quality and use of SIPs as an alternative to insulin pump therapy. Findings indicated the need for provider and care team education and training on proper SIP features, use, and prescribing.
Keyphrases
- primary care
- quality improvement
- type diabetes
- patient safety
- glycemic control
- healthcare
- palliative care
- clinical practice
- affordable care act
- cardiovascular disease
- health insurance
- emergency department
- insulin resistance
- skeletal muscle
- stem cells
- bone marrow
- mesenchymal stem cells
- electronic health record
- pain management
- smoking cessation